Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Listeria monocytogenes infection in patients with rheumatic diseases on TNF-alpha antagonist therapy: the Spanish Study Group experience.

Peña-Sagredo JL, Hernández MV, Fernandez-Llanio N, Giménez-Ubeda E, Muñoz-Fernandez S, Ortiz A, Gonzalez-Gay MA, Fariñas MC; Biobadaser group.

Clin Exp Rheumatol. 2008 Sep-Oct;26(5):854-9.

PMID:
19032819
2.

Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection.

Gómez-Reino JJ, Carmona L, Angel Descalzo M; Biobadaser Group.

Arthritis Rheum. 2007 Jun 15;57(5):756-61.

3.

Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER.

Carmona L, Gómez-Reino JJ; BIOBADASER Group.

Arthritis Res Ther. 2006;8(3):R72. Epub 2006 Apr 18.

4.

Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period.

Gomez-Reino JJ, Carmona L; BIOBADASER Group.

Arthritis Res Ther. 2006;8(1):R29. Epub 2006 Jan 6.

5.

Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.

Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, Montero D, Pascual-Gómez E, Mola EM, Carreño L, Figueroa M; BIOBADASER Group.

Arthritis Rheum. 2005 Jun;52(6):1766-72.

6.

Supplemental Content

Loading ...
Support Center